Cantor Fitzgerald Reiterates Overweight Rating on Vaxcyte, Sets $120 Target
Cantor Fitzgerald reiterated its Overweight rating on Vaxcyte and a $120 price target. The target implies 68.1% upside from the Oct. 9 close of $71.38.
Cantor Fitzgerald reiterated its Overweight rating on Vaxcyte and a $120 price target. The target implies 68.1% upside from the Oct. 9 close of $71.38.